Abstract
Esophageal cancer (EC) is the eighth most common cancer in the world and the sixth leading cause of cancer-related mortality, with esophageal squamous-cell carcinoma (ESCC) accounting for over 80% of all cases. This study aimed to estimate the cost-effectiveness of nivolumab plus chemotherapy or nivolumab plus ipilimumab compared to chemotherapy alone as first line treatment for advanced or metastatic ESCC using U.S. payer perspective
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
